Polysaccharide Storage Myopathy (PSSM1)
Gene or Region: GYS1
Reference Variant: C
Mutant Variant: T
Affected Breeds: Many
Research Confidence: High confidence - Findings reproduced multiple studies
Explanation of Results: PSSM1/PSSM1 = homozygous for Polysaccharide Storage Myopathy, extreme trait expressed PSSM1/n = heterozygous for Polysaccharide Storage Myopathy, trait expressed n/n = no variant detected
General Information for Polysaccharide Storage Myopathy (PSSM1)
Polysaccharide Storage Myopathy (PSSM) is a glycogen storage disorder in which affected horses have chronic episodes of exertional rhabdomyolysis (“tying-up”). Acute symptoms are an unwillingness to move and muscle damage following exercise. Heterozygous horses (PSSM1/n) experience more moderate symptoms that can usually be managed through a low-sugar/starch diet and exercise. However, homozygous horses (PSSM1/PSSM1) are generally more severely affected and are thus harder to manage. Additionally, one study has found that horses with PSSM1 and a malignant hyperthermia (MH) exhibit more severe clinical symptoms.
GYS1 is an enzyme involved in the production of glycogen that is found specifically within the muscle. Mutations in this gene have been associated with glycogen storage diseases in several species. This particular mutation is a single base substitution that alters an amino acid, likely affected the function of the encoded protein.
References
McCue ME et al., “Glycogen synthase (GYS1) mutation causes a novel skeletal muscle glycogenosis.” (2008) Genomics. 91: 458-66. PMID: 18358695
McCue ME et al., “Glycogen synthase 1 (GYS1) mutation in diverse breeds with polysaccharide storage myopathy.” (2008) J Vet Intern Med. 22: 1228-33. PMID: 18691366
Herszberg B et al., “A GYS1 gene mutation is highly associated with polysaccharide storage myopathy in Cob Normand draught horses.” (2009) Anim Genet. 40: 94-6. PMID: 18822097
McCue ME et al., “Polysaccharide storage myopathy phenotype in quarter horse-related breeds is modified by the presence of an RYR1 mutation.” (2009) Neuromuscul Disord. 19: 37-43. PMID: 19056269
Tryon RC et al., “Evaluation of allele frequencies of inherited disease genes in subgroups of American Quarter Horses.” (2009) J Am Vet Med Assoc. 234: 120-5. PMID: 19119976
Stanley RL et al., “A glycogen synthase 1 mutation associated with equine polysaccharide storage myopathy and exertional rhabdomyolysis occurs in a variety of UK breeds.” (2009) Equine Vet J. 41: 597-601. PMID: 19803057
Baird JD et al., “Presence of the glycogen synthase 1 (GYS1) mutation causing type 1 polysaccharide storage myopathy in continental European draught horse breeds.” (2010) Vet Rec. 167: 781-4. PMID: 21262610
McCoy AM et al., “Evidence of positive selection for a glycogen synthase (GYS1) mutation in domestic horse populations.” (2014) J Hered. 105: 163-72. PMID: 24215078
More Horse Health
Severe Combined Immunodeficiency
Severe Combined Immunodeficiency Disease (SCID) is a condition in which affected foals are unable to mount an effective immune response after infection and are unable to recover from infections that unaffected foals would easily resist. The disease is universally fatal in horses, usually within 4-6 months of life.
West Nile Virus Symptom Susceptibility / Risk
West Nile Virus (WNV) is a mosquito-borne virus that can infect multiple types of mammals, including horses. Infection can lead to a series of severe symptoms, most commonly encephalitis – acute inflammation of the brain. Severe neurological symptoms develop in ~8% of exposed horses, and once symptoms manifest, the fatality rate ranges from 20-40% and is higher in older horses.